German drug major Bayer Schering has signed a contract with the US Agency for International Development to supply up to 110 million cycles of oral contraceptives yearly for family planning programs in developing countries worldwide.
The firm will deliver up to 50 million cycles per year of Microgynon 30 ED Fe/Microlut (levonorgestrel) for public markets and up to 60 million cycles per year for social marketing programs for distribution in more than 50 USAID-supported programs worldwide, including Africa, Asia and the Middle East, Europe and Latin America.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze